Keros Therapeutics Inc (KROS NASDAQ) stock market data APIs
$11.2325
0.07(0.6%)
as of April 13, 2026
Try our APIs with
free plan!
Keros Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Prev. Close
11.2325
Open
11.3027
High
11.3782
Low
10.8238
52 wk Range
10.415-22.55
Market Cap
340 M
P/E Ratio
4.8478
Shares Outstanding
19 718 K
Revenue
244 M
EPS
-0.86
Beta
0.988
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Keros Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Keros Therapeutics Inc data using free add-ons & libraries
Get Keros Therapeutics Inc Fundamental Data
Keros Therapeutics Inc Fundamental data includes:
- Net Revenue: 244 M
- EBITDA: 72 078 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-04
- EPS/Forecast: -0.6963
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Keros Therapeutics Inc News
New
Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?
A month has gone by since the last earnings report for Keros Therapeutics, Inc. (KROS). Shares have added about 2.5% in that time frame, outperforming the S&P 500. But investors have to be wondering,...
Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?
Insmed INSM shares rallied 5.5% in the last trading session to close at $153.32. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. ...
KROS: Is the Discount Book Value a Value Trap?
Keros Therapeutics KROS posted a dramatic revenue jump in 2025, but the mix matters as much as the magnitude. The shares also trade at a steep discount to book value, creating the classic biotech ques...
KROS Stock: What to Know About Rinvatercept in DMD
Keros Therapeutics, Inc. KROS is pushing its lead asset, rinvatercept, into neuromuscular disease with Duchenne muscular dystrophy at the front of the line. The company is positioning the program arou...
Get Keros Therapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
